Effects of deprenyl on monoamine oxidase and neurotransmitters in the brains of MPTP-treated aging mice.

Deprenyl is a selective monoamine oxidase B (MAO-B) inhibitor and has been used in the treatment of Parkinson's disease. However, it is not known whether deprenyl effects are symptomatic or pharmacological. Aging mice were partially lesioned with MPTP. Control and MPTP-treated mice were given deprenyl in drinking water for 14 days. Brain tissue (including the striatum, olfactory tubercle and cerebral cortex) was assayed for MAO-B and neurotransmitter levels. The results show that deprenyl treatment, given alone or after MPTP, reduced MAO-B activity in all the three regions. No change was seen in dopamine (DA), 3,4-dihydroxyphenyl acetic acid (DOPAC), and homovanillic acid (HVA) content in any of the three areas. Cortical norepinephrine (NE) levels were also unaltered. However, striatal serotonin (5-HT) levels were decreased while its metabolite, 5-HIAA levels were significantly increased in the olfactory tubercle in animals receiving deprenyl alone. These data suggest that deprenyl treatment reduces MAO-B activity in regions in addition to the striatum without affecting norepinephrine, dopamine (DA) and its metabolites.

Differential attenuation of the responses to adenosine and methoxamine in isolated rabbit aorta.

This article describes the functional antagonism between the responses to adenosine (through adenosine A2 receptors) and methoxamine (through alpha-1 adrenoceptors) in the adventitia- and endothelium-denuded isolated rabbit thoracic aorta. Rings were contracted with different concentrations of methoxamine and cumulative relaxation concentration-response curves (CRC) to adenosine were constructed. This protocol allowed the authors to rearrange the same data, which yielded contractile CRCs to methoxamine in the presence of adenosine. A 32-fold increase in the [methoxamine] markedly attenuated the maximal response to adenosine (80% decrease) and shifted the CRC to adenosine 10-fold to the right. By contrast, a 3000-fold increase in the [adenosine] shifted the CRC to methoxamine 3.25-fold to the right and attenuated the maximal response by a modest 18%. Analysis of these data by the operational model of agonism indicated that the efficacy parameter, tau, for adenosine or methoxamine was reduced by 99% or 71%, respectively, under these conditions. The agonist dissociation constant, KA, for adenosine (80 microM) or methoxamine (33 microM) by functional antagonism was also estimated. Use of an irreversible alpha-1 adrenoceptor antagonist allowed for the estimation of the KA for methoxamine by the receptor inactivation method using the operational model (40 microM), the Furchgott equation (48 microM) and the nested equations (42 microM) described by James et al. These results suggest that this tissue preparation is a good model to study functional antagonism quantitatively and that the functional antagonism between the responses mediated by these two receptors allows for the reliable estimation of the agonist dissociation constant for alpha-1 adrenoceptor agonists.

Chronic treatment of aged mice with L-deprenyl produces marked striatal MAO-B inhibition but no beneficial effects on survival, motor performance, or nigral lipofuscin accumulation.

Male C57BL/6J mice were provided I-deprenyl (at 0, 0.5 mg/kg or 1.0 mg/kg per day) in their drinking water beginning at 18 months of age. A battery of motor tests, including open-field, tightrope, rotorod, inclined screen, runwheel, and rotodrum tests, was administered before treatment and then 6 months later at 24 months of age. A subsample of mice was retested again at 27 months of age. An untreated group of 9-month-old mice served as young controls. Deprenyl treatment reduced striatal MAO-B activity by up to 60% after 6 months on treatment but had no significant effects on striatal catecholamine levels. No significant effects of deprenyl treatment were observed on body weight, fluid intake, or survival of the mice. Chronic deprenyl treatment also did not affect motor performance in any test, except rotodrum performance at 27 months of age, which was significantly better in the 1.0 mg/kg group treated group compared to controls. No age or deprenyl effects were observed with respect to cell counts in the substantia nigra. However, nigral cells containing lipofuscin increased with age, but this neurohistochemical parameter was also unaffected by deprenyl treatment.

Kinetic characterization of adenosine A2 receptor-mediated relaxation in isolated rabbit aorta.

Previous studies in our laboratory (Wiener et al., 1991, Soc. Neurosci. Abstr. 17, 989) have addressed aspects of the functional antagonism between the responses mediated by activated adenosine A2 receptors and alpha 1-adrenoceptors in adventitia- and endothelium-denuded rabbit thoracic aortic rings by steady-state protocols which ignore the time course of response generation. In the present communication we describe aspects of the time-dependent kinetics of relaxation responses to adenosine A2 receptor agonists in tissues pre-contracted with the alpha 1-adrenoceptor agonist phenylephrine. The results were analyzed by application of the model originally developed by Keitz et al. (1990, J. Pharmacol. Exp. Ther. 255, 650) to describe the relaxation response, to a beta-adrenoceptor agonist, as a first-order exponential decrease in tissue tension over time to estimate the apparent rate constant for relaxation (krel) and the magnitude of relaxation at equilibrium. The magnitude of the relaxation responses to adenosine, N6-cyclohexyladenosine, N6-methyladenosine, 5'-N-ethylcarboxamidoadenosine, and R(-)-N6-(2-phenylisopropyl)adenosine were agonist concentration-dependent and saturable, as were the apparent rate constants for relaxation. In addition, the magnitude of the apparent rate constants for relaxation and the relaxation responses were inversely proportional to the fractional occupancy of the alpha 1-adrenoceptor. The hypothesis put forth by Keitz et al. that the maximal value of the apparent rate constant for relaxation may serve as the kinetic definition of agonist efficacy was also tested and found to be invalid for the adenosine A2 receptor. We propose that this pair of activated receptors and tissue preparation is a good model to study quantitative aspects of functional antagonism by kinetic paradigms.

Interactions between responses mediated by activation of adenosine A2 receptors and alpha 1-adrenoceptors in the rabbit isolated aorta.

1. This paper describes aspects of the functional antagonism between the responses mediated by activated alpha 1-adrenoceptors and adenosine A2 receptors in the adventitia- and endothelium-denuded aorta of the rabbit. 2. Adenosine A2 receptor agonists relaxed aortic rings pre-contracted with phenylephrine. The relaxation response was agonist concentration-dependent and saturable. The respective contractile and relaxation responses were stable, reproducible, and reversible. 3. Increasing the phenylephrine concentration caused a progressive attenuation of the action of adenosine A2 receptor agonists, consisting of a decreased maximal response and a dextral shift of the adenosine agonist concentration-response curve. This functional antagonism could be completely reversed upon removal of adenosine by either the addition of adenosine deaminase or by wash-out of the adenosine agonist from the tissue. The relaxation response to the adenosine A2 receptor partial agonists, N6-cyclohexyladenosine and R-(-)-N6-(2-phenylisopropyl)adenosine, was abolished at higher phenylephrine concentrations (e.g. 30 EC50). 4. A 1000 fold increase in the adenosine concentration was required to shift the value of the EC50 of phenylephrine six fold, while a similar increase in the value of the EC50 of adenosine could be elicited by only a 32 fold increase in the phenylephrine concentration. A 30 fold increase in the phenylephrine concentration shifted the value of the EC50 of 5'-N-ethylcarboxamidoadenosine four fold. 5. Analysis of the functional antagonism between the responses mediated by these receptors using the Black & Leff (1983) operational model of agonism allowed for the estimation of the agonist dissociation constant, KA, and the apparent efficacy, tau, for both phenylephrine and adenosine A2 receptor agonists. Increasing the concentration of phenylephrine reduced the value of tau for adenosine agonists in a concentration-dependent and saturable manner. Similarly, increasing the concentration of adenosine reduced the value of tau for phenylephrine in a concentration-dependent and saturable manner. The phenylephrine KA value obtained by the method of functional antagonism (1.9 microM) was similar to that obtained by the receptor inactivation method (2.1 microM). 6. Partial occlusion of the alpha 1-adrenoceptor by the alkylating agent, dibenamine, demonstrated that the magnitude of the adenosine A2 receptor-mediated relaxation was inversely proportional to the number of functional alpha 1-adrenoceptors. 7. It is concluded that the magnitude of functional antagonism is proportional to the stimulus elicited through either receptor. We propose that this tissue preparation and pair of receptors is a good model to study quantitative aspects of functional antagonism between activated receptors.

Kinetics of relaxation responses to vasorelaxants in intact and adventitia- and endothelium-denuded isolated rabbit thoracic aorta.

1. Although the relaxation responses to 5'-N-ethylcarboxamidoadenosine and sodium nitroprusside were stable, the relaxation response to isoproterenol partially desensitized as was observed by the partial regaining of tissue tension. 2. The apparent rate constant for relaxation by all three vasorelaxants was decreased in the presence of the adventitia and endothelium. 3. The magnitude of the relaxation responses for all three vasorelaxants and the apparent rate constant for isoproterenol desensitization were similar in intact and denuded tissues.

Allosteric interactions between the binding sites of receptor agonists and guanine nucleotides: a comparative study of the 5-hydroxytryptamine1A and adenosine A1 receptor systems in rat hippocampal membranes.

The ternary complex formed between agonist, receptor and guanine nucleotide binding protein and its destabilization by guanine nucleotides (GN) was utilized to study early events in signal transduction, by characterizing the allosteric interactions between agonist and GN binding to the receptor/guanine nucleotide binding protein, G complex for adenosine A1 and 5-hydroxytryptamine1A receptors. The functional interaction between the ternary complex and GTP was examined by assaying adenylyl cyclase activity. Binding of a full adenosine A1 agonist ([3H]-R-(-)-N6-(2-phenylisopropyl)adenosine), and a full [(+-)-[3H]-8-hydroxydipropylaminotetralin] and partial ([3H]-8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8- azaspirol[4.5]-decane-7,9-dione) 5-hydroxytryptamine1A agonist was examined in relation to the binding of GN. The amount of ternary complex formed depended upon receptor type and drug relative efficacy. The ratio between the drug's EC50 value (adenylyl cyclase) and dissociation constant (binding) was also receptor and drug relative efficacy dependent. 5'-Guanylylimidodiphosphate (100 microM) caused an approximately 50% decrease in the Bmax for all drugs without affecting Kd values. 5'-Guanylylimidodiphosphate and guanosine 5'-O-(3-thiotriphosphate) attenuated [3H]-agonist binding in a concentration-dependent and saturable manner, with IC50 values increased 2- to 6-fold with increasing receptor occupancy. IC50 values were approximately one-tenth lower at the 5-hydroxytryptamine1A receptor than adenosine A1 receptor; similar values were obtained for inhibition of (+-)-[3H]-8-hydroxydipropylaminotetralin and [3H]-8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8- azaspirol[4.5]-decane-7,9-dione binding, suggesting an independence of agonist efficacy. We propose that the stabilization of the ternary complex by hormone binding, measured by Bmax values, is related to drug-relative efficacy, thus the amount of ternary complex available for destabilization by GN is greater for the more efficacious agonist. This is translated into greater relative efficacy observed in the maximal inhibition of adenylyl cyclase.

Determination of radioligand specific activity using competition binding assays.

Radioligand binding assays are routinely utilized in laboratories throughout the world to study receptors and their related binding sites, carrier proteins, and enzymes. To accurately estimate equilibrium binding parameters, such as the equilibrium dissociation constant (Kd) and maximal number of binding sites (Bmax), the investigator must know the correct value of the specific activity of the radioligand. If the specific activity is overestimated the Kd and Bmax values will be underestimated, while underestimation of the specific activity results in an overestimation of the Kd and Bmax. The present communication describes a simple and rapid method for determining the specific activity of a radioligand using homologous competition binding assays. Performing the competition assays at two or more different concentrations of the radioligand allows the specific activity to be determined from the IC50 values without the need of analytical methods to quantify minute amounts of the radioligand. In addition to providing the specific activity, use of this method estimates the Kd for the radioligand. This method was utilized to determine the specific activity and Kd for two blockers of the dopamine uptake carrier, [3H]GBR-12935 and [3H]-CFT, which share a common binding site in the striatum.

Kinetics of relaxation responses to vasorelaxants in isolated rabbit aorta.

Transient responses of isolated tissues to drugs are best studied by application of non-steady-state protocols in which the data collected are analyzed using kinetic models. The time dependence of the relaxation response of the adventitia- and endothelium-denuded rabbit aorta to four vasorelaxants (nitroglycerin, sodium nitroprusside, 5'-N-ethylcarboxamidoadenosine and isoproterenol) was analyzed by an exploratory kinetic model. A rapid relaxation (t1/2 = 1-3 min) was elicited by all vasorelaxants. An apparent desensitization or fade of the relaxation response to nitroglycerin or isoproterenol was visualized as the partial regaining of tissue tone (t1/2 = 2-3 min). The relaxation responses to sodium nitroprusside or 5'-N-ethylcarboxamidoadenosine were stable for at least 60 min and did not exhibit an apparent regaining of tension. Tissues rendered desensitized by either isoproterenol or nitroglycerin responded fully to sodium nitroprusside or 5'-N-ethylcarboxamidoadenosine. The rate constant for relaxation was vasorelaxant concentration-dependent and saturable for all vasorelaxants. For isoproterenol, nitroglycerin, and 5'-N-ethylcarboxamidoadenosine the rate constant for relaxation was inversely proportional to the contractile stimulus, as was the magnitude of relaxation for all vasorelaxants. Although the magnitude and rate constant of the fade was not concentration-dependent for isoproterenol, it was inversely proportional to the nitroglycerin concentration. The rate constant of the fade was proportional to the contractile stimulus for isoproterenol and nitroglycerin, and the magnitude of the fade was proportional to the contractile stimulus for nitroglycerin. We propose that kinetic studies of responses in isolated vasculature supersede studies performed under steady-state conditions, for they extend our knowledge of the manner by which the steady-state is achieved and allow for a quantitative analysis of the time-dependent changes which should assist in elucidating the biochemical basis of the observed physiological response.

Sertraline and cocaine-induced locomotion in mice. I. Acute studies.

The present study assessed the behavioral and pharmacokinetic interaction between the serotonin uptake blocker sertraline and cocaine in C57BL/6ByJ mice. Pretreatment with sertraline (1-32 mg/kg IP) did not affect the total amount of spontaneous locomotor activity during 50 min following administration of cocaine (15-40 mg/kg IP). At doses of sertraline (16 and 32 mg/kg) much higher than those found to inhibit ex vivo neuronal uptake of serotonin by 50% (1-2 mg/kg), the peak of cocaine-induced locomotor activity was shifted towards a later time. A similar effect was seen after pretreatment with serotonin uptake blockers other than sertraline, and also after desipramine. Sertraline (16 and 32 mg/kg), given 60 min prior to cocaine, did not affect levels of cocaine in brain and plasma, and cocaine administration did not alter the brain level of sertraline. Although female mice were more responsive to cocaine than male mice, they were not different in their response to sertraline.

The effects of electroconvulsive shock on dopamine-1 and dopamine-2 receptor ligand binding activity in MPTP-treated mice.

To explore the possible therapeutic use of electric convulsive treatment in Parkinson's disease (PD), the authors examined the biochemical effects of electroconvulsive shock (ECS) on dopaminergic systems in a rodent model of PD, induced with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP increased dopamine turnover, as indicated by an increase in the ratio of the dopamine metabolites dihydroxyphenylacetic acid and homovanillic acid to dopamine. [3H]Spiperone binding to the D2 site increased after lesioning of striatal dopamine terminals. With ECS alone, no changes were found in monoamine levels, brain monoamine oxidase activity, or the D2-labeled sites measured 24 hours after the last treatment. [3H]SCH-23390 binding to the D1 site increased after ECS. In MPTP-treated mice, ECS also increased [3H]SCH-23390 binding to the D1 site, whereas [3H]spiperone binding to the D2 site was unchanged compared to control or to only ECS-treated animals, and decreased compared to the MPTP-treated group that did not receive ECS. ECS appears to selectively modify both the D1 and D2 sites when given after MPTP, increasing the binding of a D1 radioligand and decreasing the binding of a D2 radioligand.

Differential effects of daily administration of cocaine on hepatic and cerebral glutathione in mice.

Twenty-four hours after acute administration of cocaine HCl (25 mg/kg, i.p.) to male C57BL/6ByJ mice, there was no hepatotoxicity as measured by plasma aspartate aminotransferase (AST) activity. In contrast, daily administration of cocaine (25 mg/kg, i.p.) for 14 days induced marked hepatotoxicity, as characterized by a greater than 400% increase in plasma AST activity when assayed 24 hr after the last injection. Concomitantly, the liver had increased levels of cysteine, gamma-glutamylcysteine, glutathione, cysteinylglycine, glutamate, methionine, taurine, and aspartate. The effect appeared to be selective for compounds of the glutathione metabolic pathways, because repeated cocaine exposure did not affect other amino acids such as leucine, isoleucine, phenylalanine, serine, and valine. There was a positive correlation between the magnitude of the elevation of cysteine and the extent of liver damage. Daily cocaine administration did not affect striatal or frontal cortex glutathione. A final cocaine challenge (50 mg/kg, i.p.) did not affect either hepatic or cerebral glutathione metabolism. The increase in hepatic cysteine and glutathione upon daily cocaine administration is a potentially important compensatory mechanism against cocaine-induced hepatotoxicity.

Correlation between cocaine-induced locomotion and cocaine disposition in the brain among four inbred strains of mice.

BALB/cByJ, C57BL/6ByJ, CXBH/By, and CXBK/By mice differed in their locomotor response to cocaine measured 1-10 min after administration of 25 mg/kg IP of the compound. These differences were paralleled by differences in the disposition of cocaine (measured at 12 min) in the brain. Among all individual animals taken together, there was a significant correlation between locomotor stimulation and the brain concentration of cocaine. These results suggest that the differences between strains in their locomotor responsiveness to cocaine are determined, in part, by the disposition of cocaine in the brain following IP administration of cocaine.

Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice.

The present study examined the effect of chronic L-deprenyl on dopaminergic terminal function after mouse striatal terminals were lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 2 x 30 mg/kg s.c.). In the MPTP-lesioned mice, the level of dopamine was decreased by 59% 1 week after MPTP administration and by 22% at 16 weeks. Chronic administration of L-deprenyl (0.1 mg/kg, once weekly for up to 16 weeks) did not alter striatal dopamine metabolism, although monoamine oxidase B activity was reduced by 50% during this 16-week period, and did not alter the rate of restoration of the level of striatal dopamine.

Dopamine D1 receptor and dopamine D2 receptor binding activity changes during chronic administration of nicotine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.

The effect of nicotine on MPTP-induced changes in striatal dopamine receptors binding activity was investigated. Dopamine D1 and D2 receptors were labeled with [3H]SCH-23390 and [3H]spiperone respectively in BALB/cBy mice. With administration of only MPTP, which caused more than an 80% decrease in striatal dopamine level, binding of 0.15 nM [3H]spiperone was increased by 37%; whereas 0.3 nM [3H]SCH-23390 binding was unchanged. With chronic nicotine treatment (0.4 mg/kg twice daily for 7-9 days), [3H]SCH-23390 binding activity was increased by 27% and [3H]spiperone binding activity was unchanged. When nicotine was administered after MPTP, their separate effects could be seen in that both the D1 and D2 dopamine receptor ligand binding activities were increased and that nicotine elevated the ratio of D1/D2 receptor binding activities in MPTP-treated mice.

Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier.

L-Deprenyl is an inhibitor of monoamine oxidase B and dopamine uptake. Chronic L-deprenyl (10 mg/kg i.p., twice weekly for 4 weeks) was shown to inhibit monoamine oxidase B activity by 89%, and also to induce an up-regulation of the [3H]mazindol binding site associated with the striatal dopamine uptake carrier. Scatchard analysis indicated a 56% increase in the maximal number of [3H]mazindol binding sites in chronic L-deprenyl animals, but no effect on the affinity of these binding sites. The ability of L-deprenyl to up-regulate the [3H]mazindol-associated dopamine uptake carrier appears to be a result of its role as a dopamine uptake inhibitor.